Cargando…

Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011–2015

BACKGROUND: Medical therapy for multiple sclerosis (MS) is expensive. Quantifying the burden of MS is fundamental for health-care planning and the allocation of resources for the management of MS. This study provides current national estimates of prevalence, incidence, mortality, and costs of MS in...

Descripción completa

Detalles Bibliográficos
Autores principales: Blozik, Eva, Rapold, Roland, Eichler, Klaus, Reich, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5677381/
https://www.ncbi.nlm.nih.gov/pubmed/29138568
http://dx.doi.org/10.2147/NDT.S143180
_version_ 1783277232065609728
author Blozik, Eva
Rapold, Roland
Eichler, Klaus
Reich, Oliver
author_facet Blozik, Eva
Rapold, Roland
Eichler, Klaus
Reich, Oliver
author_sort Blozik, Eva
collection PubMed
description BACKGROUND: Medical therapy for multiple sclerosis (MS) is expensive. Quantifying the burden of MS is fundamental for health-care planning and the allocation of resources for the management of MS. This study provides current national estimates of prevalence, incidence, mortality, and costs of MS in Switzerland using claims data between 2011 and 2015. METHODS: We analyzed health insurance claims of adult persons enrolled with a large health insurance group covering about 13% of the Swiss population between 2011 and 2015. The identification of patients with MS was based on prescription data of MS-specific medication using the Anatomical Therapeutic Chemical Classification system as proxy for clinical diagnosis. We estimated prevalence, mortality, and costs of basic health insurance between 2011 and 2015. Furthermore, incidence of MS was calculated for 2015. All results were weighted with census data to achieve an extrapolation to the Swiss general population level. Cost of illness was estimated as direct medical cost from the perspective of a Swiss health insurance using multivariate linear regression analysis. RESULTS: Of the 943,639 subjects in the year 2015, 1,606 were identified as MS patients resulting in a prevalence of 190 per 100,000 (95% CI: 180−190 per 100,000). Incidence was 16 per 100,000 (95% CI: 13−19 per 100,000). According to regression analysis, the total cost of illness for basic mandatory health insurance was 26,710 Swiss Francs (CHF) (95% CI: 26,100–27,300) per person per year with the cost of medication being almost identical 26,960 CHF (95% CI: 26,170–27,800). CONCLUSIONS: MS affects 10,000–15,000 persons in Switzerland, and the prevalence has increased over the last 22 years. These persons have high need and demand for health care. High costs are primarily due to expenses for medication. Given the imbalance of MS medication therapy from the perspective of basic health insurance on the disposable resources, it is crucial to increase transparency related to the volume, type, and allocation of expenses.
format Online
Article
Text
id pubmed-5677381
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56773812017-11-14 Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011–2015 Blozik, Eva Rapold, Roland Eichler, Klaus Reich, Oliver Neuropsychiatr Dis Treat Original Research BACKGROUND: Medical therapy for multiple sclerosis (MS) is expensive. Quantifying the burden of MS is fundamental for health-care planning and the allocation of resources for the management of MS. This study provides current national estimates of prevalence, incidence, mortality, and costs of MS in Switzerland using claims data between 2011 and 2015. METHODS: We analyzed health insurance claims of adult persons enrolled with a large health insurance group covering about 13% of the Swiss population between 2011 and 2015. The identification of patients with MS was based on prescription data of MS-specific medication using the Anatomical Therapeutic Chemical Classification system as proxy for clinical diagnosis. We estimated prevalence, mortality, and costs of basic health insurance between 2011 and 2015. Furthermore, incidence of MS was calculated for 2015. All results were weighted with census data to achieve an extrapolation to the Swiss general population level. Cost of illness was estimated as direct medical cost from the perspective of a Swiss health insurance using multivariate linear regression analysis. RESULTS: Of the 943,639 subjects in the year 2015, 1,606 were identified as MS patients resulting in a prevalence of 190 per 100,000 (95% CI: 180−190 per 100,000). Incidence was 16 per 100,000 (95% CI: 13−19 per 100,000). According to regression analysis, the total cost of illness for basic mandatory health insurance was 26,710 Swiss Francs (CHF) (95% CI: 26,100–27,300) per person per year with the cost of medication being almost identical 26,960 CHF (95% CI: 26,170–27,800). CONCLUSIONS: MS affects 10,000–15,000 persons in Switzerland, and the prevalence has increased over the last 22 years. These persons have high need and demand for health care. High costs are primarily due to expenses for medication. Given the imbalance of MS medication therapy from the perspective of basic health insurance on the disposable resources, it is crucial to increase transparency related to the volume, type, and allocation of expenses. Dove Medical Press 2017-11-01 /pmc/articles/PMC5677381/ /pubmed/29138568 http://dx.doi.org/10.2147/NDT.S143180 Text en © 2017 Blozik et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Blozik, Eva
Rapold, Roland
Eichler, Klaus
Reich, Oliver
Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011–2015
title Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011–2015
title_full Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011–2015
title_fullStr Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011–2015
title_full_unstemmed Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011–2015
title_short Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011–2015
title_sort epidemiology and costs of multiple sclerosis in switzerland: an analysis of health-care claims data, 2011–2015
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5677381/
https://www.ncbi.nlm.nih.gov/pubmed/29138568
http://dx.doi.org/10.2147/NDT.S143180
work_keys_str_mv AT blozikeva epidemiologyandcostsofmultiplesclerosisinswitzerlandananalysisofhealthcareclaimsdata20112015
AT rapoldroland epidemiologyandcostsofmultiplesclerosisinswitzerlandananalysisofhealthcareclaimsdata20112015
AT eichlerklaus epidemiologyandcostsofmultiplesclerosisinswitzerlandananalysisofhealthcareclaimsdata20112015
AT reicholiver epidemiologyandcostsofmultiplesclerosisinswitzerlandananalysisofhealthcareclaimsdata20112015